Pharmacology of Parkinson's Disease
Drug strategies to restore dopaminergic-cholinergic balance in Parkinson's disease, from levodopa to MAO-B inhibitors and beyond.
Pathophysiology
Parkinson's disease (PD) results from progressive degeneration of dopaminergic neurons in the substantia nigra pars compacta. Loss of nigrostriatal dopamine disrupts the balance between the direct (movement-facilitating) and indirect (movement-inhibiting) basal ganglia pathways. Cardinal motor features are bradykinesia, rigidity, resting tremor, and postural instability. Symptoms appear after approximately 60-80% of dopaminergic neurons are lost.
Levodopa (L-DOPA)
Levodopa remains the most effective symptomatic treatment. It is the metabolic precursor to dopamine and crosses the blood-brain barrier (dopamine itself cannot). Always co-administered with a peripheral AADC inhibitor (carbidopa or benserazide) to prevent peripheral conversion, reducing nausea and increasing CNS delivery.
Motor complications emerge after 5-10 years:
- Wearing-off -- effect duration shortens between doses
- On-off fluctuations -- unpredictable switches between mobility and immobility
- Dyskinesias -- involuntary choreoathetoid movements during peak-dose periods
Dopamine Agonists
Pramipexole and ropinirole directly stimulate D2/D3 receptors. They have longer half-lives than levodopa and produce fewer dyskinesias but more psychiatric side effects (impulse control disorders, hallucinations). Rotigotine is available as a transdermal patch.
MAO-B Inhibitors
Selegiline and rasagiline selectively inhibit MAO-B, the predominant MAO isoform in the striatum, reducing dopamine degradation. They provide mild symptomatic benefit as monotherapy or extend levodopa's effect. Safinamide adds sodium channel blockade to MAO-B inhibition.
COMT Inhibitors
Entacapone and opicapone inhibit peripheral COMT, blocking the conversion of levodopa to 3-O-methyldopa. This increases levodopa bioavailability and reduces wearing-off. Stalevo is a combination of levodopa/carbidopa/entacapone.
Other Agents
- Amantadine -- weak NMDA antagonist; reduces levodopa-induced dyskinesias
- Anticholinergics -- trihexyphenidyl, benztropine restore dopaminergic-cholinergic balance; primarily for tremor; limited by cognitive side effects in elderly
- Istradefylline -- adenosine A2A antagonist for off-episodes; reduces indirect pathway overactivity
Key Takeaways
- Levodopa/carbidopa is the gold standard but causes motor complications with long-term use
- Dopamine agonists delay dyskinesias but carry impulse control disorder risk
- MAO-B and COMT inhibitors extend levodopa's effect by reducing dopamine metabolism
- No current therapy slows neurodegeneration; all treatments are symptomatic